mGluR

Metabotropic glutamate receptors

mGluR (metabotropic glutamate receptor) is a type of glutamate receptor that are active through an indirect metabotropic process. They are members of the group C family of G-protein-coupled receptors, or GPCRs. Like all glutamate receptors, mGluRs bind with glutamate, an amino acid that functions as an excitatory neurotransmitter. The mGluRs perform a variety of functions in the central and peripheral nervous systems: mGluRs are involved in learning, memory, anxiety, and the perception of pain. mGluRs are found in pre- and postsynaptic neurons in synapses of the hippocampus, cerebellum, and the cerebral cortex, as well as other parts of the brain and in peripheral tissues. Eight different types of mGluRs, labeled mGluR1 to mGluR8, are divided into groups I, II, and III. Receptor types are grouped based on receptor structure and physiological activity.
mGluR Agonists, Antagonists, Inhibitors, Modulators & Activators

(1R,2S)-VU0155041
Cat. No.: HY-14417A

(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC<sub>50</sub> of 2.35 μM.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg

(2R,4R)-APDC
Cat. No.: HY-102091

(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluR5) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-ADX-47273
Cat. No.: HY-130588

(R)-ADX-47273 is a potent mGlu5 positive allosteric modulator, with an EC<sub>50</sub> of 168 nM for potentiation.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg

(RS)-MCPG
Cat. No.: HY-100371

(RS)-MCPG (alpha-MCPG) is a competitive and selective group I/group II metabotropic glutamate receptor (mGluR) antagonist. (RS)-MCPG blocks theta-burst stimulation (TBS)-induced shifts in both juvenile and neonatal rat hippocampal neurons.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

(RS)-PPG
Cat. No.: HY-107514

(RS)-PPG is a potent and selective agonist for group III mGluRs. The EC<sub>50</sub> of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7β, and hmGluR8α, respectively. Anticonvulsive and neuroprotective activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-3,5-DHPG
Cat. No.: HY-12598

(S)-3,5-DHPG is a weak, but selective group I metabotropic glutamate receptors (mGluRs) agonist with K<sub>i</sub> values of 0.9 μM and 3.9 μM for mGluR1α and mGluR5α, respectively. (S)-3,5-DHPG exhibits anxiolytic activity in rats subjected to hypoxia.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-MCPG
Cat. No.: HY-104006

(S)-MCPG is the active isomer of (RS)-MCPG (Cat. No. HY-100371), non-selective group I/group II metabotropic glutamate receptor antagonist. In vivo: (S)-MCPG (20.8 μg) injected intraventricularly (i.c.v.)

Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

ADX-47273
Cat. No.: HY-13058

ADX-47273 is a positive allosteric modulator selective for the metabotropic glutamate receptor subtype mGluRe5(50=170 nM).

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ADX71743
Cat. No.: HY-110278

ADX71743 is a highly selective, noncompetitive and brain-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM). ADX71743 has anxiolytic-like activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ADX881878
Cat. No.: HY-18654

ADX881878 is a potent metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) with an EC<sub>50</sub> of 4 nM for human mGluR4.

Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM x 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
<table>
<thead>
<tr>
<th>Compound</th>
<th>Cat. No.</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Auglurant (VU0424238)</td>
<td>HY-16617</td>
<td>Auglurant (VU0424238) is a novel and selective mGluR5 antagonist with an IC50 value of 11 nM (rat) and an IC50 value of 14 nM (human). Auglurant (VU0424238) has an acceptable CNS penetration. Purity: 99.40% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>AZD 2066</td>
<td>HY-110255</td>
<td>AZD 2066 is a selective, orally active and brain-penetrant mGluR5 antagonist, with analgesia activity. Purity: &gt;99.0% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>AZD 9272</td>
<td>HY-110254</td>
<td>AZD 9272 is a brain penetrant mGluR5 antagonist. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>AZD-8529 mesylate</td>
<td>HY-107457A</td>
<td>AZD-8529 mesylate is a potent, highly selective and orally bioavailable positive allosteric modulator of mGluR2, with an EC50 of 285 nM, and shows no positive allosteric modulator responses at 20-25 M on the mGluR1, 3, 4, 5, 6, 7, and 8 subtypes. Purity: &gt;98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</td>
</tr>
<tr>
<td>Basimglurant (RG7090; CTEP Derivative)</td>
<td>HY-15446</td>
<td>Basimglurant (RG7090) is a potent, selective and orally available mGlu4 negative allosteric modulator with a Kd of 1.1 nM. Purity: 99.56% Clinical Data: Phase 1 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>Biphenylindanone A (BINA)</td>
<td>HY-15442</td>
<td>Biphenylindanone A (BINA) is a selective human mGluR2 (hmGluR2) potentiator for the treatment of many neurological disorders. Purity: &gt;99.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg</td>
</tr>
<tr>
<td>BMT-145027</td>
<td>HY-100728</td>
<td>BMT-145027 is an mGluR5 positive allosteric modulator without inherent agonist activity, exhibits an EC50 of 47 nM. Purity: 98.19% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>CFMTI</td>
<td>HY-100402</td>
<td>CFMTI inhibits L-glutamate–induced intracellular Ca2+ mobilization in CHO cells expressing human and rat mGluR1a, with IC50 of 2.6 and 2.3 nM, respectively. Purity: &gt;98.0% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td>CHPG</td>
<td>HY-101364</td>
<td>CHPG is a selective mGlu5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Purity: &gt;99.0% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 25 mg, 50 mg</td>
</tr>
<tr>
<td><strong>CHPG sodium salt</strong></td>
<td><strong>Cat. No.: HY-101364A</strong></td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>CHPG sodium salt is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 5 mg, 10 mg, 25 mg, 50 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CPPG</strong> (RS)-CPPG</th>
<th><strong>Cat. No.: HY-101333</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CPPG (RS)-CPPG is a potent group II/III mGlu receptors antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50 = 2.2 nM) over group II (IC50 = 46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CPPHA</strong></th>
<th><strong>Cat. No.: HY-14612</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CPPHA is a selective positive allosteric modulator of mGluR5 receptor.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 95.01%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>DCG-IV</strong></th>
<th><strong>Cat. No.: HY-101335</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, respectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1R/5R=389/630 μM) and III receptors (IC50: mGlu4R/6R/7R/8R= 22.5/39.6/40.1/32 μM).</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 1 mg, 5 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>DFMTI</strong> (MK5435)</th>
<th><strong>Cat. No.: HY-100404</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DFMTI can completely block the rmGlu1 L757V glutamate response. In vitro: DFMTI can completely block the rmGlu1 L757V glutamate response, although significantly higher concentrations were required to induce blockade.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.32%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Decoglurant</strong> (RO4995819)</th>
<th><strong>Cat. No.: HY-16766</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Decoglurant (RO4995819) is a novel, long-acting, orally bioavailable allosteric antagonist of mGlu5 receptor with IC50 of 2.2 nM, and shows &gt;1000-fold selectivity over other mGlu receptors.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.43%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>DHPG</strong> (RS)-3,5-DHPG</th>
<th><strong>Cat. No.: HY-12598A</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DHPG (RS)-3,5-DHPG is an amino acid, which acts as a selective and potent agonist of group I mGluRs (mGlu1 and mGlu5), shows no effect on Group II or Group III mGluRs. DHPG (RS)-3,5-DHPG is also an effective antagonist of mGluRs linked to phospholipase D.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;97.0%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 5 mg, 10 mg, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Dipraglurant</strong> (ADX48621)</th>
<th><strong>Cat. No.: HY-14859</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dipraglurant (ADX 48621) is a mGluR5 antagonists with IC50 of 0.021 μM.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> 99.99%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> Phase 2</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>E4CPG</strong></th>
<th><strong>Cat. No.: HY-100372</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>E4CPG is a group I/group II metabotropic glutamate receptor antagonist, more potent than (RS)-MCPPG.</td>
<td></td>
</tr>
<tr>
<td><strong>Purity:</strong> &gt;98.0%</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Data:</strong> No Development Reported</td>
<td></td>
</tr>
<tr>
<td><strong>Size:</strong> 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
<td></td>
</tr>
</tbody>
</table>
EGLU
((2S)-α-Ethylglutamic acid; (25)-α-EGLU)
Cat. No.: HY-101332

EGLU (2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (S(3S))-ACPD-sensitive site with a Kᵢ value of 66 µM. EGLU is an antidepressant agent. /br>
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fenobam
Cat. No.: HY-101478

Fenobam is a selective, orally active, and non-competitive mGluR5 antagonist acting at an allosteric modulatory site (Kᵢ values are 54 and 31 nM for rat and human recombinant mGlu5 receptors, respectively).
Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Foliglurax
(PXT002331)
Cat. No.: HY-108703

Foliglurax (PXT002331) is a highly selective and potent, brain-penetrant metabotropic glutamate receptor 4 positive allosteric modulator (mGluR4 PAM) with an EC₅₀ of 79 nM. Antiparkinsonian effect.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FPTQ
Cat. No.: HY-100382

FPTQ is mGluR1 antagonist with IC₅₀ of 6 nM and 1.4 nM for human and mouse mGluR1 respectively. Inhibit [3H]FTIDC target: mGluR1 IC₅₀: 6 nM In vivo: FPTQ exhibited dose-dependent and plasma concentration-dependent receptor occupancy in the cerebellum and striatum.
Purity: 99.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

HTL14242
(HTL0014242)
Cat. No.: HY-W062697

HTL14242 (HTL0014242) is an advanced, orally active and potent mGlu5 NAM with a pKᵢ and pIC₅₀ value of 9.3 and 9.2, respectively. HTL14242 can be used for the study of Parkinson’s disease.
Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JNJ-40411813
(ADX-71149)
Cat. No.: HY-15748

JNJ-40411813 (ADX-71149) is a novel positive allosteric modulator of the metabotropic Glutamate 2 receptor (mGlu2R) with EC₅₀ of 147 nM.
Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

www.MedChemExpress.com
JNJ-42153605
Cat. No.: HY-18162

JNJ-42153605 is a positive allosteric modulator of the metabotropic glutamate 2 (mGlu2) receptor with an EC₅₀ of 17 nM.

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ-46778212
(VU 0409551)
Cat. No.: HY-19559

JNJ-46778212 (VU 0409551) is an mGlu5 positive allosteric modulator with an EC₅₀ of 260 nM.

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-APB
(L-AP 4)
Cat. No.: HY-100781A

L-APB is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 2.49 μM for mGlu5, mGlu6, mGlu8, and mGlu1 receptors, respectively.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Cysteinesulfinic acid monohydrate
Cat. No.: HY-W017230

L-Cysteinesulfinic acid monohydrate is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀'s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lu AF21934
Cat. No.: HY-100366

Lu AF21934 is a selective and brain-penetrant mGlu4 receptor positive allosteric modulator with an EC₅₀ of 500 nM for mGlu4 receptor.

Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

L-APB is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 2.49 μM for mGlu5, mGlu6, mGlu8, and mGlu1 receptors, respectively.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Cysteinesulfinic acid
Cat. No.: HY-100804

L-Cysteinesulfinic acid is a potent agonist at several rat metabotropic glutamate receptors (mGluRs) with pEC₅₀'s of 3.92, 4.6, 3.9, 2.7, 4.0, and 3.94 for mGluR1, mGluR5, mGluR2, mGluR4, mGluR6, and mGluR8, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

L-Glutamine
(L-Glumatic acid 5-amide)
Cat. No.: HY-N0390

L-Glutamine is a non-essential amino acid present abundantly throughout the body and is involved in gastrointestinal disorders. Target: mGluR
Glutamine (abbreviated as Gln or Q) is one of the 20 amino acids encoded by the standard genetic code.

Purity: >98.0%
Clinical Data: Launced
Size: 10 mM × 1 mL, 100 mg, 500 mg

LY 541850
Cat. No.: HY-103551A

LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells. LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC₅₀ values of 0.161 μM and 0.038 μM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg
LY2140023  
Cat. No.: HY-14554  
LY2140023 is an orally active prodrug of LY404039. LY404039 is a selective metabotropic glutamate 2/3 receptor agonist. LY2140023 has the potential for schizophrenia.

Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

LY2794193  
Cat. No.: HY-119243  
LY2794193 is a highly potent and selective mGlu3 receptor agonist (hmGlu3 \(K_i=0.927\) nM, \(\text{mEC}_{50}=0.47\) nM, \(\text{hmGlu2}K_i=412\) nM, \(\text{mEC}_{50}=475\) nM).

Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

LY2812223  
Cat. No.: HY-18760  
LY2812223 is a highly potent, functionally selective mGlu receptor agonist with mGlu binding affinity for mGlu2, and mGlu4 (\(K_i=144\) nM and 156 nM, respectively).

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

LY3020371 hydrochloride  
Cat. No.: HY-123820  
LY3020371 hydrochloride is a potent, selective metabotropic glutamate 2/3 receptor (mGlu2/3) antagonist with \(K_i\) of 5.3 and 2.5 nM, potently blocks cAMP formation with IC50 of 16.2 nM. LY3020371 hydrochloride exerts an antidepressant-like signature in vivo.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

LY341495  
Cat. No.: HY-70059  
LY341495 is a metabotropic glutamate receptor (mGluR) antagonist with IC50 of 21 nM, 14 nM. 7.8 \(\mu\)M, 8.2 \(\mu\)M, 170 nM, 990 nM, 22 \(\mu\)M for mGlu2, mGlu3, mGlu1a, mGlu5a, mGlu8, mGlu7, and mGlu4 receptors, respectively.

Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

LY367385  
Cat. No.: HY-107515  
LY367385 is a highly potent and selective mGluR1a antagonist. LY367385 has an IC50 of 8.8 \(\mu\)M for inhibits of quisqualate-induced phosphoinositide (PI) hydrolysis, compared with >100 \(\mu\)M for mGlu5a.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 1 mg

LY404039  
Cat. No.: HY-50906  
LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor.

Purity: >98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Mavoglurant  
(AFQ056)  
Cat. No.: HY-15257  
Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.

Purity: 99.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mavoglurant racemate  
(AFQ-056 racemate)  
Cat. No.: HY-15257A  
Mavoglurant racemate (AFQ-056 racemate) is the racemate of Mavoglurant. Mavoglurant is a novel, non-competitive mGlu5 receptor antagonist.

Purity: 98.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg

www.MedChemExpress.com
### Methoxy-PEPy
**Cat. No.:** HY-12510

Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist with IC50 of 1 nM. IC50 value: 1 nM Target: mGlu5R inhibitor Administration of [3H]methoxy-PEPy (50 microCi/kg i.v.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

### mGluR2 antagonist 1
**Cat. No.:** HY-133555

mGluR2 antagonist 1 is a highly potent, orally bioavailable and selective class of mGluR2 negative allosteric modulator (IC50) of 9 nM with excellent brain permeability.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### MPEP
**Cat. No.:** HY-14609A

MPEP is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype (IC50 = 36 nM) and a positive allosteric modulator at mGlu4 receptors. IC50 value: 36 nM Target: mGlu5 Centrally active following systemic administration in vivo.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### MSOP
**Cat. No.:** HY-101226

MSOP is a selective group III metabotropic glutamate receptor antagonist with apparent Ks of 51 μM for the L-AP4-sensitive presynaptic mGluR.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 5 mg

### NPEC-caged-LY379268
**Cat. No.:** HY-110304

NPEC-caged-LY379268 is a type II mGluR agonist.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### O-Phospho-L-serine
**Cat. No.:** HY-15129

O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8).

- **Purity:** >98.0%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg

### MFZ 10-7 hydrochloride
**Cat. No.:** HY-103575A

MFZ 10-7 hydrochloride is a highly potent and selective mGluR5 NAM (negative allosteric modulator), with a Kd of 0.67 nM for rat mGlu5. MFZ 10-7 hydrochloride inhibits cocaine-taking and cocaine-seeking behavior in rats.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### MTEP hydrochloride
**Cat. No.:** HY-14609

MTEP hydrochloride is a potent and highly selective non-competitive antagonist at the mGlu5 receptor subtype with IC50 of 36 nM.

- **Purity:** 99.69%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg

### ML289
**Cat. No.:** HY-19630

ML289 (VU0463597) is a potent, selective, and CNS-penetrant mGlu3 (IC50=0.66 μM) negative allosteric modulator. ML289 displays >15-fold selectivity over mGlu2 and is inactive against mGlu5.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### MTFZ 10-7 hydrochloride
**Cat. No.:** HY-13206

MTFZ 10-7 hydrochloride is a potent, selective and non-competitive mGlu5 antagonist with an IC50 of 5 nM and a Kd of 16 nM. MTFZ hydrochloride produces antiparkinsonian-like effects.

- **Purity:** 99.73%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg

### MTP289
**Cat. No.:** HY-14108

MTP289 (VU0463597) is a potent, selective, and CNS-penetrant mGlu3 (IC50=0.66 μM) negative allosteric modulator. MTP289 displays >15-fold selectivity over mGlu2 and is inactive against mGlu5.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 1 mg, 5 mg

### MTP389
**Cat. No.:** HY-12510

MTP389 is a selective group III metabotropic glutamate receptor antagonist with apparent Ks of 51 μM for the L-AP4-sensitive presynaptic mGluR.

- **Purity:** >98%
- **Clinical Data:** No Development Reported
- **Size:** 10 mM × 1 mL, 10 mg, 50 mg
PHCCC

PHCCC is a Group I metabotropic glutamate receptor antagonist with EC50 of 6 μM and a positive allosteric modulator of mGluR4. Also as a potent to antagonism for mGluR2 and mGluR8.

Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

QUISQUALIC ACID

Quisqualic acid (L-Quisqualic acid), a natural analog of glutamate, is a potent and pan two subsets (iGluR and mGluR) of excitatory amino acid (EAA) agonist with an EC_{50} of 45 nM and a K_i of 10 nM for mGluR1R. Quisqualic acid is isolated from the fruits of Quisqualis chinensis.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0357121

VU0357121 is a novel positive and highly selective allosteric modulator (PAM) of mGlu5R with EC50 of 33 nM. IC50 Value: 33 nM(EC50) Target: mGlu5R in vitro: VU0357121 do not bind at the MPEP allosteric site of mGlu5, thus do not possess mGlu5 NAM activity.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

VU0364439

VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM. IC50 Value: 19.8 nM(EC50) Target: mGlu4R in vitro: in vivo: VU 0364439 possess less than ideal PK properties preventing their use as in vivo tools.

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

VU0364770

VU0364770 is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0364770 exhibits EC_{50} of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively.

Purity: 99.57%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

www.MedChemExpress.com
VU0364770 hydrochloride

Cat. No.: HY-100588A

VU0364770 hydrochloride is a selective and potent positive allosteric modulator (PAM) of mGlu4. VU0346770 hydrochloride exhibits EC_{50} of 290 nM and 1.1 μM at rat mGlu4 and human mGlu4 receptor, respectively.

Purity: 99.82%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

VU0650786

Cat. No.: HY-108710

VU0650786 is a potent and selective CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 (mGlu3 NAM), with an IC_{50} of 392 nM. VU0650786 has antidepressant and anxiolytic activity in rodents.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

VU0652835

Cat. No.: HY-119941

VU0652835 is a metabotropic glutamate receptor subtype 5 (mGlu5) negative allosteric modulator with an IC_{50} of 81 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU6001376

Cat. No.: HY-112814

VU6001376 is a potent and selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4 PAM) with an EC_{50} of 50.1 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU6005649

Cat. No.: HY-107982

VU6005649 is a CNS penetrant mGlu_{7,8} receptor agonist with EC_{50} of 0.65 μM and 2.6 μM for mGlu_{7} receptor and mGlu_{8} receptor, respectively.

Purity: 98.91%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VU6012962

Cat. No.: HY-114403

VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC_{50} of 347 nM.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Xanthurenic acid

Cat. No.: HY-W01466

Xanthurenic acid is a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus.

Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg